A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-Week Cycle in Patients With Advanced Malignancies.

Trial Profile

A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-Week Cycle in Patients With Advanced Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Pracinostat (Primary) ; Azacitidine
  • Indications Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 02 Dec 2014 Results from the phase I portion in elderly patients with acute myeloid leukaemia published in an MEI Pharma media release.
    • 19 Dec 2012 Results from the phase II part in patients with myelodysplastic syndromes were presented at the 54th Annual Meeting of the American Society of Hematology according to a MEI Pharma media release.
    • 06 Nov 2012 Results from the phase II part in patients with myelodysplastic syndromes will be presented at the Annual Meeting of the American Society of Hematology in December 2012, according to a MEI Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top